Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
- DOI
- 10.1093/annonc/mdx289
- Published
- 2017-09
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/annonc/mdx289,
title = {Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma},
author = {M. Dreyling and F. Morschhauser and K. Bouabdallah and D. Bron and D. Cunningham and S.E. Assouline and G. Verhoef and K. Linton and C. Thieblemont and U. Vitolo and F. Hiemeyer and M. Giurescu and J. Garcia-Vargas and I. Gorbatchevsky and L. Liu and K. Koechert and C. Peña and M. Neves and B.H. Childs and P.L. Zinzani},
year = {2017},
journal = {Annals of Oncology},
doi = {10.1093/annonc/mdx289},
url = {https://doi.org/10.1093/annonc/mdx289}
}RIS
TY - JOUR TI - Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma AU - M. Dreyling AU - F. Morschhauser AU - K. Bouabdallah AU - D. Bron AU - D. Cunningham AU - S.E. Assouline AU - G. Verhoef AU - K. Linton AU - C. Thieblemont AU - U. Vitolo AU - F. Hiemeyer AU - M. Giurescu AU - J. Garcia-Vargas AU - I. Gorbatchevsky AU - L. Liu AU - K. Koechert AU - C. Peña AU - M. Neves AU - B.H. Childs AU - P.L. Zinzani PY - 2017 JO - Annals of Oncology DO - 10.1093/annonc/mdx289 UR - https://doi.org/10.1093/annonc/mdx289 ER -
APA
Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B., & Zinzani, P. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology. https://doi.org/10.1093/annonc/mdx289
Source records
- crossref · retrieved 2026-09-25T10:26:55.278Z